ClinicalTrials.gg
RecruitingNCT05646394Updated Dec 9, 2025

Registry on Augmented Antithrombotic Treatment Regimens for Patients With Arterial Thrombotic APS

An observational study in Antiphospholipid Syndrome and Arterial Thrombosis, sponsored by McMaster University. Recruiting at 3 sites in 2 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2025-12-09.

Sponsored by McMaster University · Observational

How we know

From the registry’s dates

  • Started Jul 2022; still recruiting 4 years 4 months later.

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Study type
Observational
Model
Cohort
Time perspective
Prospective
Enrollment
150
Ages
18 Years and older
Sex
All
01

Study summary

The goal of this registry is to gather more information on the efficacy and safety of various antithrombotic regimens. The registry collects data on patients with antiphospholipid syndrome and an arterial event within the past 12 months, on treatment with either A) a VKA with therapeutic range, INR 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0, C) a VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen. The follow-up is 2 years.

Read the detailed description

The optimal antithrombotic management of patients with antiphospholipid syndrome and arterial thrombotic events is unclear. The guidelines provide several options, mostly with vitamin K antagonist with/without an antiplatelet agent. Dual antiplatelet therapy (DAPT) was in a meta-analysis potentially effective, but included studies were few and small.

The primary aim is to compare a vitamin K antagonist (VKA), i.e. warfarin, acenocoumarol, phenprocoumon etc, with international normalized ratio 2.0-3.0 plus low-dose aspirin (75-100 mg) with DAPT - typically low-dose aspirin plus clopidogrel (75 mg daily) but other combinations will be acceptable. The registry will also include patients treated with VKA alone at standard- or high-intensity, since this is recommended and will serve as reference groups in comparison with VKA + low-dose aspirin and versus DAPT. The outcomes are (efficacy) arterial or venous thromboembolism, vascular death or (safety) major bleeding.

A secondary objective is to analyze how the cardiovascular risk factors (hypertension, hyperlipidemia, obesity, smoking, diabetes, and heart failure), venous thrombotic risk factors (previous venous thromboembolism, cancer, immobility, chronic inflammatory disease) and anti-phospholipid profile contribute to recurrent arterial thrombosis.

02

Conditions studied

  • Antiphospholipid Syndrome
  • Arterial Thrombosis

Keywords

  • anticoagulation
  • vitamin K antagonist
  • antiaggregant
  • stroke
  • myocardial infarction
  • hemorrhage
03

In context

Antiphospholipid Syndrome

121 studies on the registry are indexed under Antiphospholipid Syndrome; 52 are open to participants now.

This study's planned enrollment of 150 is close to the median of 156 across 50 observational studies indexed under Antiphospholipid Syndrome.

Browse Antiphospholipid Syndrome studies →

Lead sponsor

McMaster University is the lead sponsor of 742 studies on the registry; 127 are open to participants now.

Of its 7 completed or terminated interventional studies of FDA-regulated products, 3 (43%) have results posted.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No
Sampling method
Non-probability sample

Study population

The decision on the treatment regimen should have been made by the treating physician on clinical grounds and judgement, prior to informing the patients about the registry. The information should include that vitamin K antagonist is the recommended standard, either alone or in combination and, in case dual antiplatelet regimen is chosen, an explanation to the patient for what reasons it should be used or continued. Patients that have been started on either of the eligible regimens after the most recent arterial thromboembolic event and within the past 12 months can be approached and informed about the study. If the patient meets the inclusion criteria and does not have any of the exclusion criteria, the investigator or designated representative obtains consent for collection of data.

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  1. Patients of at least 18 years of age with confirmed antiphospholipid syndrome according to Sydney criteria and with first or recurrent arterial thrombotic manifestation, including those with asymptomatic brain infarcts on diagnostic imaging.
  2. Treatment with either A) a vitamin K antagonist (VKA) with therapeutic range, (INR) 2.0-3.0 plus low-dose aspirin (75-100 mg daily), B) a VKA alone with therapeutic range, INR 2.0-3.0 or C) VKA with therapeutic range, INR 3.0-4.0, or D) with a dual antiplatelet regimen, if considered appropriate by the treating physician.
  3. Signed obtained (in jurisdictions where required).

Exclusion criteria

Exclusion Criteria:

  1. Inability to follow the patient due to geographical or other reasons.
  2. Patients with documented poor compliance.
  3. Bleeding risk that in the opinion of the treating physician makes combination antithrombotic therapy unsafe.
  4. Pregnancy or planned pregnancy.
  5. Venous thrombotic event diagnosed after the last arterial event.
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

INR, PT and aPTT (clotting tests)

Blood tests of how long blood takes to clot. The INR is the prothrombin time (PT) put on a common scale; about 1 is usual for someone not taking a blood thinner.

Criteria often make an exception for people on a blood thinner such as warfarin, whose INR is raised on purpose.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Observational model
Cohort
Time perspective
Prospective
Enrollment
150 participants (estimated)
Target follow-up
2 Years
Patient registry
Yes

Interventions

  • DrugDual antiplatelet therapy

    Aspirin plus any of clopidogrel, ticagrelor or prasugrel

    Also known as: Aspirin, Plavix, Brilinta, Effient

  • DrugCombined antithrombotic therapy

    Combination of a vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with low-dose aspirin.

    Also known as: Vitamin K antagonist plus aspirin, Vitamin K antagonist plus antiaggregant, Vitamin K antagonist plus antiplatelet agent

  • DrugVitamin K antagonist standard intensity

    vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 2.0-3.0

    Also known as: VKA

  • DrugVitamin K antagonist high intensity

    vitamin K antagonist, such as warfarin, acenocoumarol, phenprocoumon, phenindione etc, with therapeutic range, international normalized ratio 3.0-4.0

    Also known as: VKA

06

What researchers measure

Primary outcomes

  1. Number of Participants with thromboembolism verified by diagnostic imaging, electrocardiogram or troponin rise

    Composite of arterial thrombosis (stroke, myocardial infarction, peripheral arterial thrombosis or embolism), venous thromboembolism (thrombosis in any deep vein or pulmonary embolism), and vascular death.

    Time frame: 2 years

  2. Number of Participants with major hemorrhage fulfilling at least one of the International Society on Thrombosis and Haemostasis criteria

    Major hemorrhage according to the International Society on Thrombosis and Haemostasis

    Time frame: 2 years

Secondary outcomes

  1. Number of Participants with arterial thrombosis verified by diagnostic imaging

    stroke, myocardial infarction, peripheral arterial thrombosis or embolism

    Time frame: 2 years

  2. Number of Participants with venous thromboembolism verified by diagnostic imaging

    thrombosis in any deep vein or pulmonary embolism

    Time frame: 2 years

  3. Number of Participants with vascular death verified by diagnostic imaging, electrocardiogram or troponin rise

    Death due to arterial or venous thromboembolism

    Time frame: 2 years

07

Study locations

3 of 3 sites recruiting
08

References and documents

Individual participant data

Plan to share: Yes — The study protocol and ICF are available on the ISTH website (under SSC - RedCap. IPD will be shared after the primary publication.

Supporting information: Study protocol, Informed consent form

Time frame: Study protocol and ICF are available now and for 10 years after the end of the study. IPD will be available after the primary data have been published and for 10 years

Access criteria: A research plan is required.

09

Timeline

Tracking since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reached

Started Jul 2022 (actual). Primary completion is estimated for Jul 2029, 84 months after the start.

How these figures are worked out, and which studies are left out of them.

Registered
Dec 5, 2022
First posted
Dec 12, 2022
StartActual
Jul 1, 2022
Primary completionEst.
Jul 31, 2029
CompletionEst.
Dec 31, 2029
Last update
Dec 9, 2025
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Dec 9, 2025, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05646394
Collaborators
International Society on Thrombosis and Haemostasis
Responsible party
Sponsor
First posted
Dec 12, 2022
Start date
Jul 1, 2022
Primary completion
Jul 31, 2029 (estimated)
Completion
Dec 31, 2029 (estimated)
Last update
Dec 9, 2025

Study contacts

Sam Schulman, MD, PhD
Contact
schulms@mcmaster.ca
+19055270271 ext. 44810
Hannah Cohen, MD, FRCP
Contact
hannah.cohen@ucl.ac.uk
+442034477368 ext. 9456
Cary Clark
study director · International Society on Thrombosis and Haemostasis

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion